Pay in 4 interest-free payments of $5.10 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Aronne reports receiving grants or personal fees from Altimmune, AstraZeneca, Boehringer Ingelheim, Eli Lilly, ERX, Gelesis, Intellihealth, Jamieson Wellness, Janssen, Novo Nordisk, Optum, Pfizer, Senda Biosciences, and Versanis and being a shareholder of Allurion, ERX Pharmaceuticals, Gelesis, Intellihealth, and Jamieson Wellness
Ozempic has also demonstrated significant weight loss effects, with patients losing up to 15% of their body weight
Key takeaways Retatrutide isn't approved yet and isn't expected to launch in the UK until at least mid-2026 In clinical trials, target doses ranged from 0.5mg to 12mg weekly, with the most common being 4mg, 8mg, 9mg and 12mg Different dosing schedules were tested, with most people starting at 2mg and escalating every 4 weeks The 12mg dose produced the most weight loss (up to 28.7% after 68 weeks) Starting at 2mg rather than 4mg helped reduce side effects during escalation First to know Get an email the day retatrutide launches in the UK
Jastreboff AM, Aronne LJ, Ahmad NN et al (2022) Tirzepatide once weekly for the treatment of obesity
We have patients who routinely surpass this rate of weight loss
US$ 28.45
US$ 24.88
US$ 23.43
US$ 25.56
